Ceftriaxone in the Management of Bipolar Depression

Stopped early · Not applicable

Conditions studied: Bipolar Depression

In brief

We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.

Key facts

Study ID

NCT00566111

Run by

Yale University

People needed

5

Starts

2007-09-01

Expected to finish

2009-12-01

Last updated by the study team

2020-03-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DSM-IV diagnosis of bipolar disorder
• Presence of a current major depressive episode on the SCID
• Score of 17 or greater on the HDRS
• Failure to respond to two previous medication trials
• Capable of giving voluntary written consent

You may not qualify if…

• Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis
• Significant current substance dependence/abuse within 3 months preceding the trial
• Significant history of intravenous drug abuse
• Active suicidal ideation
• Pregnant/lactating mothers
• Significant medical history
• Patients on anticoagulation treatment
• Patients who test positive for HIV or Hep B or C

Where it is running

• Yale University School of Medicine — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.